Capecitabine–Based Chemoradiation Therapy in the Preoperative Treatment of Rectal Cancer


Capecitabine–Based Chemoradiation Therapy in the Preoperative Treatment of Rectal Cancer
Slides from presentations at ASCO 2011 and comments from Charles D Blanke, MD and Steven R Alberts, MD

Roh MS et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. Proc ASCO 2011;Abstract 3503.

Hofheinz R et al. Capecitabine (cape) versus 5-fluorouracil (5-FU)-based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, Phase III trial. Proc ASCO 2011;Abstract 3504.

Dr Blanke is Vice-President of Systemic Therapy at the BC Cancer Agency and Head of the Division of Medical Oncology at the University of British Columbia in Vancouver, British Columbia, Canada.

Dr Alberts is Professor of Oncology at Mayo Clinic College of Medicine in Rochester, Minnesota.